Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. EWTX
stocks logo

EWTX

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
9 Analyst Rating
up Image0
Wall Street analysts forecast EWTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EWTX is 42.13 USD with a low forecast of 14.00 USD and a high forecast of 51.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
1 Hold
0 Sell
Strong Buy
up Image0
Current: 14.800
sliders
Low
14.00
Averages
42.13
High
51.00
up Image0
Current: 14.800
sliders
Low
14.00
Averages
42.13
High
51.00
Wedbush
Laura Chico
Buy
Maintains
$43
2025-04-21
Reason
Wedbush
Laura Chico
Price Target
$43
2025-04-21
Maintains
Buy
Reason
Scotiabank
Louise Chen
Buy
to
Hold
Downgrades
$50 → $14
2025-04-03
Reason
Scotiabank
Louise Chen
Price Target
$50 → $14
2025-04-03
Downgrades
Buy
to
Hold
Reason
Scotiabank analyst Louise Chen downgraded Edgewise Therapeutics to Sector Perform from Outperform with a $14 price target.
RBC Capital
Leonid Timashev
Buy
Maintains
$56 → $52
2025-04-03
Reason
RBC Capital
Leonid Timashev
Price Target
$56 → $52
2025-04-03
Maintains
Buy
Reason
RBC Capital analyst Leonid Timashev lowered the firm's price target on Edgewise Therapeutics to $52 from $56 and keeps an Outperform rating on the shares after the company reported 28-day CIRRUS Part B/C data for EDG-7500 in patients with obstructive or nonobstructive hypertrophic cardiomyopathy. The firm believes the drug has shown "compelling and highly meaningful efficacy" and contends that that the risk of afib is "both manageable and more likely than not unrelated to '7500." With shares selling of significantly, the firm would be buyers given it sees compelling activity across Edgewise's programs. The firm believes additional data catalysts will provide "further evidence that these programs can succeed and drive a combined $5B+ revenue opportunity," the analyst added.
Piper Sandler
Yasmeen Rahimi
Buy
Maintains
$51
2025-04-02
Reason
Piper Sandler
Yasmeen Rahimi
Price Target
$51
2025-04-02
Maintains
Buy
Reason
Edgewise intends to use the net proceeds from the offering to support the potential U.S. commercial launch of sevasemten in patients with Becker muscular dystrophy, if approved, and advancement of a Phase 3 trial with sevasemten in Duchenne muscular dystrophy, Phase 3 trials of EDG-7500 in patients with obstructive and non-obstructive hypertrophic cardiomyopathy and Edgewise's other ongoing research and development programs, and for working capital and general corporate purposes. Leerink, Piper Sandler, Guggenheim and Truist are acting as joint book running managers for the offering. The deal priced at last night's closing price of $20.13.
Scotiabank
Louise Chen
Buy
Initiates
$50
2025-03-07
Reason
Scotiabank
Louise Chen
Price Target
$50
2025-03-07
Initiates
Buy
Reason
RBC Capital
Leonid Timashev
Buy
Reiterates
$56
2025-03-04
Reason
RBC Capital
Leonid Timashev
Price Target
$56
2025-03-04
Reiterates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Edgewise Therapeutics Inc (EWTX.O) is -8.21, compared to its 5-year average forward P/E of -10.98. For a more detailed relative valuation and DCF analysis to assess Edgewise Therapeutics Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-10.98
Current PE
-8.21
Overvalued PE
-3.81
Undervalued PE
-18.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-7.31
Current EV/EBITDA
-5.28
Overvalued EV/EBITDA
-0.53
Undervalued EV/EBITDA
-14.09

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 132.09% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

EWTX News & Events

Events Timeline

(ET)
2025-05-08
08:05:36
Edgewise Therapeutics reports Q1 EPS (43c), consensus (42c)
select
2025-05-06 (ET)
2025-05-06
13:07:28
Controversial doctor Vinay Prasad named CBER director, STAT reports
select
link
2025-04-21 (ET)
2025-04-21
12:17:11
RBC sees Makary interview as potentially positive for biotech stocks
select
Sign Up For More Events
Sign Up For More Events

News

Preview
1.0
05-14PRnewswire
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025

  • Company Presentation Announcement: Edgewise Therapeutics will present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025, at 9:00 am ET, with a live webcast available for viewers.

  • About Edgewise Therapeutics: The company specializes in developing innovative treatments for muscular dystrophies and cardiac conditions, including their lead products Sevasemten and EDG-7500, currently in late-stage clinical trials.

Preview
9.5
05-08PRnewswire
Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

  • Clinical Trial Progress: Edgewise Therapeutics announced positive results from the Phase 2 CIRRUS-HCM trial for EDG-7500 in hypertrophic cardiomyopathy and is on track to report data from its Duchenne muscular dystrophy trials (LYNX and FOX) in Q2 2025.

  • Financial Update: The company strengthened its financial position with approximately $188 million in net proceeds from a recent public offering, bringing its pro-forma cash balance to over $624 million as of March 31, 2025.

Preview
4.0
05-01TipRanks
3 Best Stocks to Buy Now, 5/1/2025, According to Top Analysts

  • Top Stock Picks: Analysts recommend three stocks as Strong Buys: Meta Platforms (META) with a 25% upside, Waystar Holding Corp. (WAY) with a 28.25% upside, and Edgewise Therapeutics (EWTX) with an impressive 186.6% upside potential.

  • Analyst Ratings: All three stocks have received consistent Buy ratings from top analysts, indicating strong confidence in their future performance according to TipRanks' Analyst Top Stocks tool.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Edgewise Therapeutics Inc (EWTX) stock price today?

The current price of EWTX is 14.8 USD — it has increased 0.14 % in the last trading day.

arrow icon

What is Edgewise Therapeutics Inc (EWTX)'s business?

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions. It has built its muscle-focused drug discovery platform. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. Its lead product candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy. Its product candidate, EDG-7500, for the treatment of hypertrophic cardiomyopathy addition to exploring the potential of its mechanism in the treatment of disorders of diastolic dysfunction.

arrow icon

What is the price predicton of EWTX Stock?

Wall Street analysts forecast EWTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EWTX is 42.13 USD with a low forecast of 14.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Edgewise Therapeutics Inc (EWTX)'s revenue for the last quarter?

Edgewise Therapeutics Inc revenue for the last quarter amounts to -45.96M USD, increased 32.24 % YoY.

arrow icon

What is Edgewise Therapeutics Inc (EWTX)'s earnings per share (EPS) for the last quarter?

Edgewise Therapeutics Inc. EPS for the last quarter amounts to -37910000.00 USD, increased 31.20 % YoY.

arrow icon

What changes have occurred in the market's expectations for Edgewise Therapeutics Inc (EWTX)'s fundamentals?

The market is revising No Change the revenue expectations for EWTX for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -44.51%.
arrow icon

How many employees does Edgewise Therapeutics Inc (EWTX). have?

Edgewise Therapeutics Inc (EWTX) has 88 emplpoyees as of May 20 2025.

arrow icon

What is Edgewise Therapeutics Inc (EWTX) market cap?

Today EWTX has the market capitalization of 1.56B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free